rethinkPeptides Search
Menu
Study breakdown

Shared CGRP Genetics Between Migraine and Gut Disorders Suggests Anti-CGRP Drugs Could Treat Both

evidence
The takeaway

Genetic analysis reveals extensive shared genetic architecture between migraine and gastrointestinal disorders, with shared CGRP gene variants suggesting anti-CGRP migraine drugs might benefit diverticular disease and inflammatory bowel disease.

CGRP genes shared

CALCA/CALCB (encoding CGRP) showed concordant local genetic correlation between migraine and diverticular disease, IBD, and ulcerative colitis — suggesting anti-CGRP drugs could benefit these GI conditions

What the researchers found

Migraine showed strong genetic correlation with non-immune GI disorders: IBS (rg = 0.37, p = 10⁻²¹), GERD, PUD, FD, and DD. No correlation was found with IBD. However, local genetic sharing at the CALCA/CALCB genes (encoding CGRP) was concordant and significant for diverticular disease, IBD, and ulcerative colitis, suggesting anti-CGRP therapies could benefit these conditions.

Mendelian randomization supported causal effects of some GI conditions on migraine — particularly diverticular disease (OR 1.90, p = 2.2 × 10⁻⁴) — but not of migraine on GI conditions. CNS-related genes were enriched in the genetic overlap of GERD, IBS, and PUD with migraine, supporting neurologic mechanisms.

Why it matters

If CGRP plays a shared role in both migraine and certain GI disorders, then anti-CGRP drugs — which have proven transformative for migraine — could potentially be repurposed for diverticular disease and inflammatory bowel disease. This genetic evidence provides the rationale for clinical trials exploring these new applications of CGRP-targeting peptide therapies.

How the study worked

Genome-wide genetic correlation analysis using summary statistics from large-scale GWAS studies for migraine (including by aura status), IBS, PUD, GERD, FD, DD, IBD, UC, and CD. Local genetic correlation was assessed at independent genome regions. Enrichment analysis examined tissue specificity of shared genes. Mendelian randomization assessed potential causal relationships. Specific attention was paid to CALCA/CALCB (CGRP) and serotonin-related loci.

What this study cannot tell us

Genetic correlation does not prove shared mechanisms — the same genes could act through different pathways in different tissues. The Mendelian randomization results suggest GI conditions cause migraine but not vice versa, which is counterintuitive and may reflect methodological limitations. GWAS data is primarily from European populations. The study does not prove anti-CGRP drugs would work for GI conditions — clinical trials are needed.

How to read the evidence

This is a large-scale genetic epidemiology study using genome-wide summary statistics from multiple GWAS. While it provides robust statistical evidence for shared genetics, it cannot prove that anti-CGRP drugs would be effective for GI conditions — clinical trials are needed to establish therapeutic benefit.

When this study was published

Published in 2024, this study provides timely genetic evidence supporting the potential repurposing of anti-CGRP migraine drugs for gastrointestinal conditions.

The bigger picture

This study fundamentally connects the migraine-CGRP story to gastroenterology. CGRP has long been known to be present in the gut, but its role in GI disease has been underexplored compared to its role in migraine. The genetic evidence that CGRP variants contribute to both migraine and GI conditions suggests CGRP may be a master regulator of neuro-gut communication, with implications for a new class of gastroenterology therapeutics.

Questions still open

  • Would anti-CGRP antibodies (erenumab, fremanezumab) improve outcomes in diverticular disease or inflammatory bowel disease?
  • Does CGRP act through the same receptor pathways in the gut as in the trigeminal system?
  • Could migraine patients with comorbid IBS benefit more from anti-CGRP therapy than those without GI comorbidities?

Common questions

Could anti-CGRP migraine drugs treat gut problems too?
This genetic study found that the same CGRP gene variants contribute to both migraine and certain GI conditions (diverticular disease, IBD, ulcerative colitis). This suggests that drugs targeting CGRP — already proven for migraine — might also help these gut conditions. However, clinical trials are needed before this can be confirmed.
Why do migraine and IBS often occur together?
This study shows they share extensive genetic risk factors, particularly in genes active in the central nervous system. The genetic correlation between migraine and IBS (rg = 0.37) is among the strongest found, supporting the concept of a shared neurological basis — often called the gut-brain axis — underlying both conditions.

Read the original research

Shared Genetics of Migraine and Gastrointestinal Disorders Implicates Underlying Neurologic Mechanisms Yet Heterogeneous Etiologies.

Neurology. Genetics, 10(6), e200201

Citation

Chasman, Daniel I; Guo, Yanjun; Chan, Andrew T; Rist, Pamela M; Staller, Kyle. (2024). Shared Genetics of Migraine and Gastrointestinal Disorders Implicates Underlying Neurologic Mechanisms Yet Heterogeneous Etiologies.. Neurology. Genetics, 10(6), e200201. https://doi.org/10.1212/NXG.0000000000200201